Key Clinical Message:
Renal involvement in SpA should not be missed, screening these patients
during follow-up allows early detection of any impairment and helps
guide early nephroprotection and treatment measures. AA amyloidosis, IgA
nephropathy and urolithiasis are the most reported, however, other rare
involvement can be described.